Sana Biotechnology, Inc.

NasdaqGS:SANA Stock Report

Market Cap: US$564.9m

Sana Biotechnology Management

Management criteria checks 3/4

Sana Biotechnology's CEO is Steve Harr, appointed in Sep 2018, has a tenure of 6.17 years. total yearly compensation is $2.67M, comprised of 24.7% salary and 75.3% bonuses, including company stock and options. directly owns 3.97% of the company’s shares, worth $22.41M. The average tenure of the management team and the board of directors is 1.2 years and 5.3 years respectively.

Key information

Steve Harr

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage24.7%
CEO tenure6.2yrs
CEO ownership4.0%
Management average tenure1.2yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

Sana Biotechnology: The Story Becomes Murkier

Nov 19

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Nov 01
We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Jul 14

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Jul 12
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Sana Biotechnology: Now In Overbought Territory

Mar 17

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Jan 11

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Dec 30
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 14
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

May 26
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology: Exciting Preclinical Science

Feb 12

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Oct 13
Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Sana Biotechnology: Hypoimmune Cell Therapies

Jul 01

Sana Biotechnology reports Q1 results

May 05

CEO Compensation Analysis

How has Steve Harr's remuneration changed compared to Sana Biotechnology's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$306m

Jun 30 2024n/an/a

-US$245m

Mar 31 2024n/an/a

-US$309m

Dec 31 2023US$3mUS$659k

-US$283m

Sep 30 2023n/an/a

-US$276m

Jun 30 2023n/an/a

-US$362m

Mar 31 2023n/an/a

-US$320m

Dec 31 2022US$4mUS$645k

-US$269m

Sep 30 2022n/an/a

-US$300m

Jun 30 2022n/an/a

-US$298m

Mar 31 2022n/an/a

-US$207m

Dec 31 2021US$1mUS$611k

-US$356m

Sep 30 2021n/an/a

-US$358m

Jun 30 2021n/an/a

-US$327m

Mar 31 2021n/an/a

-US$433m

Dec 31 2020US$7mUS$535k

-US$285m

Compensation vs Market: Steve's total compensation ($USD2.67M) is about average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Harr (54 yo)

6.2yrs

Tenure

US$2,671,662

Compensation

Dr. Steven D. Harr, also known as Steve, M.D., is President and Chief Executive Officer at Sana Biotechnology, Inc. since September 2018 and also serves as its Director since October 2018. He served as the...

Leadership Team

NamePositionTenureCompensationOwnership
Steven Harr
President6.2yrsUS$2.67m3.97%
$ 22.4m
Susan Wyrick
Acting CFOless than a yearno data0.066%
$ 373.2k
Snehal Patel
Senior VP & Chief Technical Officerless than a yearno datano data
Dhavalkumar Patel
Executive VP & Chief Scientific Officerless than a yearno datano data
Bernard Cassidy
Executive VP2.2yrsUS$4.26m0.042%
$ 234.8k
Sonja Schrepfer
Senior VP & Head of Hypoimmune Platform5.8yrsno datano data
Farah Anwar
Head of Development Operations4yrsno datano data
Gary Meininger
Chief Medical Officer1.6yrsno datano data
Yuko Soneoka
Head of Intellectual Propertyless than a yearno datano data
John Gerecitano
Head of Oncology Research & Developmentless than a yearno datano data

1.2yrs

Average Tenure

54yo

Average Age

Experienced Management: SANA's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Steven Harr
President6.1yrsUS$2.67m3.97%
$ 22.4m
Robert Taylor Nelsen
Independent Director6.1yrsUS$294.80k0.0062%
$ 35.0k
Mary Wilderotter
Independent Director4.5yrsUS$314.80k0.0032%
$ 18.0k
Douglas Cole
Independent Director4.6yrsUS$302.30k0.091%
$ 511.9k
Patrick Yang
Independent Director6.1yrsUS$299.80k0.067%
$ 377.6k
Michelle Seitz
Independent Director4yrsUS$314.80k0%
$ 0
Richard Mulligan
Vice Chairman6yrsno data1.21%
$ 6.8m
Hans Edgar Bishop
Independent Chairman of the Board6.1yrsUS$354.80k2.59%
$ 14.6m
Joshua Bilenker
Independent Director3.9yrsUS$299.80k0.0090%
$ 50.6k
Alise Reicin
Independent Director3.9yrsUS$302.30k0%
$ 0

5.3yrs

Average Tenure

62.5yo

Average Age

Experienced Board: SANA's board of directors are considered experienced (5.3 years average tenure).